Fortunately, they were able to knock that on the head quite quickly, something that non clinicians find more challenging to do
Recommended by endocrinologists Change needs to start from within
But, you know, Im extremely curious about everything going on, and being able to ask brilliant minds about it is fun
Exploratory analyses revealed exenatide significantly reduced heavy drinking days and total alcohol intake in a subgroup of obese patients. Senior author Professor Anders Fink-Jensen told medscape.com: Something is happening in the brain, and activation of the reward centre is hampered by the GLP-1 compound. And he noted: If patients with AUD already fulfill the criteria for semaglutide (or other GLP-1 analogs) by having type 2 diabetes and/or a Body Mass Index (BMI) over 30kg/m2, they can of course use the compound right now. Professor Fink-Jensens team is also beginning a study in patients with AUD and a BMI greater than 30 kg/m2 to investigate the effects on alcohol intake of semaglutide up to 2.4 mg weekly (the maximum dose currently approved for obesity patients in the US)
Our guide on how to inject GLP-1 peptides covers the technique in full detail with illustrations
doi: 10.1242/dev.090571 73 GabelH